FDA Finalizes Guidance on Prescription Drug Use-Related Software
The FDA's final guidance codifies how the agency will regulate software functions that support prescribed drugs, giving life-sciences clients a clearer framework for digital features in combination products.
FDA has issued final guidance titled "Regulatory Considerations for Prescription Drug Use-Related Software," finalizing the September 2023 draft and setting out how the agency intends to apply its statutory authorities to software that supports prescription drug use.
The practical significance is clarity on regulatory pathway. Software functions that merely help a patient take a drug as directed — reminders, adherence prompts, dose logging — are generally not devices and fall outside FDA premarket requirements. Functions that recommend dosing, or that drive dosing decisions, typically cross into device jurisdiction and may require clearance or approval, potentially as a combination product. The guidance also bears on labeling and marketing claims, shaping promotion review, enforcement exposure, and product liability risk.
Counsel advising pharma and digital-health clients should check earlier comment-driven compliance programs against the current text. Watch for how FDA applies the framework in its next device classification and promotional-enforcement activity, whether Congress or FDA revisits digital health provisions, and whether prospective software or AI-specific statutory changes alter the framework. The guidance is non-binding, so compliance analysis should rest on underlying law.